Foundation Medicine

Boston, Massachusetts, United States (specifically, 400 Summer Street, Boston's Seaport District)  All United States companies → Founded 2010
Point-of-Care Diagnostics Specialty-Focused AI
Oncology Pathology
Drug Discovery & Research Oncology AI Pathology AI
Acquired by Roche (Roche acquired full ownership in 2018 for approximately $2.4 billion, valuing the company at $5.3 billion) — $198M (prior to acquisition by Roche)

Products

FoundationOne
Foundation Medicine
Drug Discovery & Research
FoundationOne offers FDA-approved, AI-assisted comprehensive genomic profiling for solid tumors, helping physicians inform cancer treatment and identify clinical trial opportunities.

See all 1 product →

About Foundation Medicine

Foundation Medicine is a global, patient-focused precision medicine company dedicated to transforming cancer care through comprehensive genomic profiling (CGP). The company develops, manufactures, and sells genomic profiling assays based on next-generation sequencing (NGS) technology. These tests, such as FoundationOne CDx, FoundationOne Liquid CDx, and FoundationOne Heme, analyze hundreds of genes to identify genomic alterations that drive cancer growth in solid tumors, hematologic malignancies, and sarcomas.

For physicians, Foundation Medicine’s portfolio provides critical insights to help guide personalized treatment strategies for advanced cancer patients. The company’s reports match a patient’s unique tumor genomic profile to relevant targeted therapies, immunotherapies, and clinical trial options. By leveraging a continuously growing genomic database, which includes over 800,000 genomic profiles, Foundation Medicine aims to make CGP the global standard of care, enabling more informed treatment decisions and accelerating the development of new cancer therapies.

Focus Areas

Genomic profiling precision medicine cancer care next-generation sequencing companion diagnostics solid tumors hematologic malignancies sarcomas real-world data AI-powered tools molecular residual disease (MRD)

Business Intelligence

Key InvestorsThird Rock Ventures, Google Ventures, Kleiner Perkins Caufield & Byers, Cascade Investment, Casdin Capital, Deerfield Management, GV
PartnershipsNovartis, Bristol Myers Squibb, National Cancer Institute (NCI) ComboMATCH, ECOG-ACRIN Cancer Research Group, ConcertAI, Epic, Syndax Pharmaceuticals
AcquisitionsAcquired by Roche in 2018. Recently acquired SAGA Diagnostics' molecular residual disease (MRD) platform, Pathlight (via Roche's merger agreement to acquire SAGA).
TechnologyNext-generation sequencing (NGS) technology, comprehensive genomic profiling (CGP) assays, FoundationCore database, AI-powered tools, liquid biopsy, whole genome sequencing (WGS) germline test (for research use), molecular residual disease (MRD) platform (Pathlight)
FDA Clearances2 cleared products (estimated)

What Physicians Need to Know

Genomic Profiling & Precision Medicine
Foundation Medicine specializes in comprehensive genomic profiling (CGP) for a wide range of cancers, including solid tumors, hematologic malignancies, and sarcomas. They provide a deep understanding of genomic mutations to inform personalized treatment plans and advance precision medicine.
Next-Generation Sequencing (NGS)
Their core technology involves advanced next-generation sequencing (NGS) assays, including both DNA and RNA sequencing, to detect a broad spectrum of genomic alterations, fusions, and structural variants.
Companion Diagnostics (CDx)
Foundation Medicine is a leader in companion diagnostic (CDx) development and approvals, offering FDA-authorized and regulatory-authorized tests that help match patients with relevant targeted therapies and immunotherapies.
Liquid Biopsy & MRD Monitoring
They offer plasma-based comprehensive genomic profiling (liquid biopsy) for non-invasive tumor profiling and monitoring. Their portfolio is expanding in molecular residual disease (MRD) monitoring, including FoundationOneu00ae Monitor and the integration of SAGA Diagnostics' Pathlight platform for ultra-sensitive detection of cancer recurrence.
Real-World Data & AI-Powered Tools
Foundation Medicine leverages real-world data and AI-powered tools to accelerate therapy development and expand the information provided by their diagnostic solutions, aiming for improved patient outcomes. They collaborate with Flatiron Health on the Clinico-Genomic Database (CGDB).
Physician Tip

For physicians, Foundation Medicine stands out by providing actionable insights through comprehensive, validated reports that summarize critical biomarker and genomic findings upfront. Their tests, performed in CAP Accredited and CLIA approved labs, help guide treatment strategies, identify targeted therapies, immunotherapies, and clinical trial options for advanced cancer patients. They offer educational resources, decision support, and are committed to ensuring equitable access through broad insurance coverage and financial assistance programs. The integration of their data with EHR systems (e.g., Epic's Aura Network) aims to streamline workflows and enhance patient care.

Foundation Medicine actively collaborates with biopharmaceutical companies for therapy development and research. They have a strategic collaboration with Flatiron Health to integrate genomic and clinical treatment/outcomes data into a cloud-based information platform (Clinico-Genomic Database). They are also working on integrating their services with Electronic Health Record (EHR) systems, having launched their first integration with Epic's Aura Network.

Products by Foundation Medicine

1 product in the directory

FoundationOne
Foundation Medicine
Drug Discovery & Research
FoundationOne offers FDA-approved, AI-assisted comprehensive genomic profiling for solid tumors, helping physicians inform cancer treatment and identify clinical trial opportunities.

What the Web Says

Foundation Medicine is a molecular information company focused on transforming cancer care through genomic profiling assays. The company generally receives positive reviews for its mission-driven culture, innovative technology, and patient-centric approach. However, some employee reviews highlight challenges with management, rapid growth leading to evolving processes, and occasional issues with work-life balance in certain departments.

Overall: Positive

Strengths

  • Strong patient-first culture and meaningful work.
  • Innovative technology and cutting-edge science in cancer research.
  • Good pay and benefits, including competitive wages, yearly bonuses, and 401K matching.
  • Supportive culture and collaborative environment.
  • Opportunities for growth, learning, and career advancement.
  • Flexible work arrangements, including remote work options.

Limitations

  • Challenging environment with too many layers of management and inexperienced leadership in some departments.
  • Rapid growth can lead to evolving culture and business process challenges.
  • Work-life balance can be an issue in some teams due to heavy workloads.
  • Limited job security and advancement opportunities in certain roles.
  • Occasional software crashes and limited customization in some product offerings (referring to 'Foundation' software, not Foundation Medicine's core genomic profiling products).
  • High cost of tests, though often covered by insurance or financial assistance.

Based on reviews from: Indeed.com, Reddit, Nebula Genomics (review site), Rannkly, Comparably, YouTube (healthcare IT reviewer), Capterra, G2

Last updated: 2026-07-26

Videos

News, demos, and interviews about Foundation Medicine.

Loading videos...

Videos load interactively. If none appear, search YouTube for Foundation Medicine →

View all on YouTube

No press coverage or publications on file yet. Know of some? Suggest an edit →

Frequently Asked Questions

Foundation Medicine's CGP assays, such as FoundationOne CDx and FoundationOne Liquid CDx, provide genomic insights for advanced solid tumors by analyzing hundreds of cancer-related genes and genomic signatures. For hematologic malignancies and sarcomas, FoundationOne Heme offers specialized DNA and RNA sequencing. These tests identify actionable genomic alterations, guiding targeted therapies, immunotherapies, and clinical trial options to personalize cancer care.
Foundation Medicine offers FDA-approved NGS-based in vitro diagnostic tests, FoundationOne CDx (tissue-based) and FoundationOne Liquid CDx (blood-based), for comprehensive genomic profiling. Additionally, FoundationOne Heme is a laboratory-developed test for hematologic malignancies and sarcomas. FoundationOne CDx and FoundationOne Liquid CDx serve as companion diagnostics, identifying patients who may benefit from specific targeted therapies, with the company holding 100 approved companion diagnostic indications across the US and Japan.
Foundation Medicine is advancing its molecular residual disease (MRD) offerings with FoundationOne Tracker, a personalized circulating tumor DNA (ctDNA) monitoring assay that received FDA Breakthrough Device designation for early-stage cancer. They are also strengthening their portfolio with SAGA Diagnostics' Pathlight, a tumor-informed MRD platform utilizing whole genome sequencing and digital PCR for ultra-sensitive detection, which is covered by Medicare for early-stage breast cancer recurrence monitoring. FoundationOne Monitor is also available as a laboratory developed test for tracking ctDNA in solid malignant neoplasms.
Foundation Medicine utilizes real-world data and AI-powered tools to accelerate personalized therapy development and expand diagnostic solutions. They collaborate with Flatiron Health to create the Clinico-Genomic Database (CGDB), integrating genomic data with de-identified clinical data from EHRs. This robust resource provides comprehensive insights into cancer and patient outcomes, supporting research and informing clinical decision-making.
Foundation Medicine's FDA-approved tests adhere to FDA and CLIA/CAP regulations, ensuring quality and compliance. All tests are covered by Original Medicare and Medicare Advantage for qualifying patients, often with no out-of-pocket costs, and the company offers a needs-based financial assistance program. Their FoundationAccess program provides comprehensive billing and reimbursement support, including prior authorizations and appeals, alongside professional services to aid clinical decision-making.
Foundation Medicine maintains extensive strategic partnerships with biopharmaceutical companies to develop companion diagnostics and advance biomarker-driven therapies, as well as collaborations with Natera and SAGA Diagnostics for MRD solutions. As an independent affiliate of the Roche group, acquired in 2018, Foundation Medicine benefits from strong company stability and a long-term commitment to advancing precision oncology, while retaining autonomy to collaborate across the industry.

Investors

Who's funded Foundation Medicine.

Related Companies

Clarista is a healthcare AI company that focuses on building a “trust layer” for enterprise AI, particularly within regulated industries like healthcare and financial services. The company’s platform aims to address the challenges of data fragmentation, governance, and compliance that often hinder the successful implementation of AI projects in large organizations. Clarista’s technology unifies structured […]

HelloBooks.ai is an AI-powered accounting software company that aims to automate and simplify financial management for small businesses, freelancers, and accounting professionals. The platform utilizes generative AI to handle repetitive bookkeeping tasks such as transaction categorization, receipt capture, bank reconciliation, and report generation. It is designed to reduce manual data entry and improve accuracy, allowing […]

Vero, also known as Vero.ai, is an artificial intelligence company specifically designed to augment clinical workflows and improve patient care within the healthcare sector. Their primary focus is on leveraging AI to streamline administrative tasks, enhance diagnostic accuracy, and personalize treatment plans. By automating routine processes, Vero aims to free up healthcare professionals’ time, allowing […]

Ant Group, a global digital technology provider and operator of Alipay, has significantly expanded its focus into healthcare AI. The company recently upgraded its physician platform, Haodf for Doctor, into ‘AQ for Doctor,’ an AI-powered workstation designed to support physicians across various stages of clinical practice, including online consultations, patient management, clinical decision support, and […]

e4health is a healthcare consulting and services company that provides innovative solutions to hospitals, health systems, outpatient providers, and physician practices. The company focuses on addressing data, quality, and revenue challenges within the healthcare ecosystem. Their services are designed to streamline health information data and workflows, optimize coding, quality, and clinical documentation integrity processes, and […]

PayZen is a healthcare AI company dedicated to solving the healthcare affordability crisis for both patients and providers. The company’s AI-powered platform offers personalized, interest-free, and fee-free patient financing solutions, enabling patients to manage their medical bills through affordable payment plans tailored to their unique ability to pay. This approach aims to increase access to […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.